RankAlpha logo
Back to Rankings

DNTH

Dianthus TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary sources show multiple shots on goal around claseprubart: early CAPTIVATE GO language in CIDP, a planned gMG Phase 3 start in mid-2026, and MMN data in 2H 2026, while March 2026 FDA feedback reduced a visible screening/safety-framing overhang across trials [#10-K-2026-03-09] [#8-K-2026-03-26].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +8.8.
What can break
Clinical readouts remain binary and can overwhelm favorable operational updates.
Momentum
92
Value
41
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $82.00 · Bull $115.00 · Bear $55.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $84.92
Why
Momentum92 · Δ7d +8.8
Value41 · Δ7d +0.1
Sentiment50 · Δ7d -0.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendImproving
Δ7d
+8.8
Δ21d
-3.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
50
33% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+4.9
Why this grade

Composite grade B. Momentum 91.6 / Value 41.1 / Sentiment 49.5

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.89B
Beta
1.59
Shares Out
42.88M
P/E (TTM) · Derived
-44.7
P/S (TTM)
513.87
P/FCF (TTM) · Derived
-37.66
Rev YoY
-81.8%
EPS YoY
-32.3%
Gross Margin
-
Op Margin
-4558.4%
Net Debt
-$275.24M
Current Ratio
17.35
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology